Findings related to effectiveness ( treatment discontinuation , quality of life , and neurocognitive improvements ) were generally consistent with those observed in non-Chinese population s. No new safety signals specific for Chinese population s were raised for olanzapine .
Chinese and non-Chinese population s with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses .
BACKGROUND Despite the burden of schizophrenia and bipolar disorder in the Chinese population , country-specific data to guide practitioners regarding antipsychotic therapy are lacking .
Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects.
AIM To compare the pharmacokinetic profiles and dose proportionality of olanzapine in Chinese and Caucasian subjects . METHODS R and omized , three-period study with 12 Chinese and 12 Caucasian , healthy , male subjects administered 2.5 , 5 and 10 mg olanzapine . Noncompartmental pharmacokinetic parameters were derived . RESULTS No statistically significant racial differences in the weight-normalized pharmacokinetic parameters were observed except for Vz/Fnorm , which was 17 % lower at the 5- and 10-mg dose in the Chinese group ( 95 % confidence interval 8.49 , 10.1 and 8.05 , 9.73 , respectively ) , compared with the Caucasian group ( 9.53 , 12.8 and 9.39 , 12.0 , respectively ) .  Olanzapine 's pharmacokinetics were linear and dose proportional in both racial groups . CONCLUSION The pharmacokinetics of olanzapine are similar in both Chinese and Caucasian racial groups
Findings related to effectiveness ( treatment discontinuation , quality of life , and neurocognitive improvements ) were generally consistent with those observed in non-Chinese population s. No new safety signals specific for Chinese population s were raised for olanzapine .
Chinese and non-Chinese population s with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses .
BACKGROUND Despite the burden of schizophrenia and bipolar disorder in the Chinese population , country-specific data to guide practitioners regarding antipsychotic therapy are lacking .